Abstract
As we enter an era of precision medicine and targeted therapies in the treatment of metastatic cancer, we face new challenges for patients and providers alike as we establish clear guidelines, regulations, and strategies for implementation. At the crux of this challenge is the fact that patients with advanced cancer may have disproportionate expectations of personal benefit when participating in clinical trials designed to generate generalizable knowledge. Patient and physician goals of treatment may not align, and reconciliation of their disparate perceptions must be addressed. However, it is particularly challenging to manage a patient's expectations when the goal of precision medicine—personalized response—exacerbates our inability to predict outcomes for any individual patient. The precision medicine informed consent process must therefore directly address this issue. We are challenged to honestly, clearly, and compassionately engage a patient population in an informed consent process that is responsive to their vulnerability, as well as ever-evolving indications and evidence. This era requires a continual reassessment of expectations and goals from both sides of the bed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 386-388 |
| Number of pages | 3 |
| Journal | Oncologist |
| Volume | 23 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2018 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Revisiting Expectations in an Era of Precision Oncology. / Marchiano, Emily J.; Birkeland, Andrew C.; Swiecicki, Paul L.; Spector-Bagdady, Kayte; Shuman, Andrew G.
In: Oncologist, Vol. 23, No. 3, 03.2018, p. 386-388.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Revisiting Expectations in an Era of Precision Oncology
AU - Marchiano, Emily J.
AU - Birkeland, Andrew C.
AU - Swiecicki, Paul L.
AU - Spector-Bagdady, Kayte
AU - Shuman, Andrew G.
PY - 2018/3
Y1 - 2018/3
N2 - As we enter an era of precision medicine and targeted therapies in the treatment of metastatic cancer, we face new challenges for patients and providers alike as we establish clear guidelines, regulations, and strategies for implementation. At the crux of this challenge is the fact that patients with advanced cancer may have disproportionate expectations of personal benefit when participating in clinical trials designed to generate generalizable knowledge. Patient and physician goals of treatment may not align, and reconciliation of their disparate perceptions must be addressed. However, it is particularly challenging to manage a patient's expectations when the goal of precision medicine—personalized response—exacerbates our inability to predict outcomes for any individual patient. The precision medicine informed consent process must therefore directly address this issue. We are challenged to honestly, clearly, and compassionately engage a patient population in an informed consent process that is responsive to their vulnerability, as well as ever-evolving indications and evidence. This era requires a continual reassessment of expectations and goals from both sides of the bed.
AB - As we enter an era of precision medicine and targeted therapies in the treatment of metastatic cancer, we face new challenges for patients and providers alike as we establish clear guidelines, regulations, and strategies for implementation. At the crux of this challenge is the fact that patients with advanced cancer may have disproportionate expectations of personal benefit when participating in clinical trials designed to generate generalizable knowledge. Patient and physician goals of treatment may not align, and reconciliation of their disparate perceptions must be addressed. However, it is particularly challenging to manage a patient's expectations when the goal of precision medicine—personalized response—exacerbates our inability to predict outcomes for any individual patient. The precision medicine informed consent process must therefore directly address this issue. We are challenged to honestly, clearly, and compassionately engage a patient population in an informed consent process that is responsive to their vulnerability, as well as ever-evolving indications and evidence. This era requires a continual reassessment of expectations and goals from both sides of the bed.
UR - http://www.scopus.com/inward/record.url?scp=85043358860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043358860&partnerID=8YFLogxK
U2 - 10.1634/theoncologist.2017-0269
DO - 10.1634/theoncologist.2017-0269
M3 - Article
C2 - 29158373
AN - SCOPUS:85043358860
VL - 23
SP - 386
EP - 388
JO - Oncologist
JF - Oncologist
SN - 1083-7159
IS - 3
ER -